Hu-Lieskovan, Siwen
Bhaumik, Srabani
Dhodapkar, Kavita
Grivel, Jean-Charles J B
Gupta, Sumati
Hanks, Brent A
Janetzki, Sylvia
Kleen, Thomas O
Koguchi, Yoshinobu
Lund, Amanda W
Maccalli, Cristina
Mahnke, Yolanda D
Novosiadly, Ruslan D
Selvan, Senthamil R
Sims, Tasha
Zhao, Yingdong
Maecker, Holden T
Clinical trials referenced in this document:
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
https://doi.org/10.1016/s0140-6736(14)60958-2
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
https://doi.org/10.1016/j.clinthera.2015.02.018
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2022-sitc2022.0608
Documents that mention this clinical trial
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
https://doi.org/10.1136/jitc-2020-000775
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Documents that mention this clinical trial
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
https://doi.org/10.1136/jitc-2020-000775
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
https://doi.org/10.1136/jitc-2021-002757
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
https://doi.org/10.1136/jitc-2023-008325
Documents that mention this clinical trial
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2020-000674
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
https://doi.org/10.1136/jitc-2022-004742
604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2022-sitc2022.0604
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
https://doi.org/10.1136/jitc-2021-002646
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
https://doi.org/10.1136/jitc-2019-000313
Documents that mention this clinical trial
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
https://doi.org/10.1136/jitc-2020-000650
73 Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab
https://doi.org/10.1136/jitc-2022-sitc2022.0073
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
579 Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab
https://doi.org/10.1136/jitc-2022-sitc2022.0579
365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.365
269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer
https://doi.org/10.1136/jitc-2020-sitc2020.0269
583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
https://doi.org/10.1136/jitc-2022-sitc2022.0583
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
https://doi.org/10.1136/jitc-2023-sitc2023.0605
Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743
674 Late antibiotic administration during durvalumab treatment may be associated with clinical benefit
https://doi.org/10.1136/jitc-2020-sitc2020.0674
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Clinical Validation of Mathematically Derived Early Tumor Dynamics for Solid Tumors in Response to Durvalumab
https://doi.org/10.1200/cci.23.00254
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
https://doi.org/10.1136/jitc-2020-001225
Chimeric antigen receptor T cell therapy in childhood leukaemia
https://doi.org/10.1136/archdischild-2024-328263
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002056
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
https://doi.org/10.1200/jco.22.00642
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002287
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data
https://doi.org/10.1136/jitc-2025-011819
468 Classification of patients who do not develop early CRS/ICANS in relapsed/refractory large B-cell lymphoma using ZUMA clinical trial data
https://doi.org/10.1136/jitc-2024-sitc2024.0468
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002056
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma
https://doi.org/10.1007/s40262-024-01413-z
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
https://doi.org/10.1136/bmjopen-2018-026644
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-002903
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705